We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
+$387M
Cap. Flow
+$515M
Cap. Flow %
30.44%
Top 10 Hldgs %
76.07%
Holding
31
New
6
Increased
13
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$129M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$45.8M
3
CLDX icon
Celldex Therapeutics
CLDX
+$43.6M
4
IMCR icon
Immunocore
IMCR
+$38.7M
5
CGON icon
CG Oncology
CGON
+$25.6M

Top Sells

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$21.4M
2
VERA icon
Vera Therapeutics
VERA
+$5.25M
3
NTRA icon
Natera
NTRA
+$2.97M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$2.86M
5
COGT icon
Cogent Biosciences
COGT
+$1.34M

Sector Composition

Rank Sector Weight
1 Healthcare 89.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
26
ProQR Therapeutics
PRQR
$243M
$4.64M 0.27%
+1,750,000
New +$5.56M
RLAY icon
27
Relay Therapeutics
RLAY
$4.02B
$4.12M 0.24%
+1,000,000
New +$5.44M
CRBU icon
28
Caribou Biosciences
CRBU
$156M
$3.83M 0.23%
2,406,147
+50,000
+2% +$101K
SLRN
29
DELISTED
ACELYRIN
SLRN
$2.66M 0.16%
847,366
– –
CLYM
30
Climb Bio
CLYM
$735M
$985K 0.06%
+547,000
New +$1.98M
VRTX icon
31
PUT
Vertex Pharmaceuticals
VRTX
$121B
– –
-30,000
Closed -$14M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Kynam Capital Management held 31 positions worth $1.69B, up 30% from $1.3B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Kynam Capital Management deployed $515M of net new capital in Q4 2024, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was Immunocore: 1,225,576 shares worth $36.2M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Dynavax Technologies, an estimated $21.4M trimmed.

  • Kynam Capital Management's largest Q4 2024 buy was Immunocore: 1,225,576 shares worth $36.2M.
  • Kynam Capital Management added most to Vaxcyte in Q4 2024, an estimated $129M increase.
  • Kynam Capital Management's biggest Q4 2024 reduction was Dynavax Technologies, cutting an estimated $21.4M.
  • Kynam Capital Management's ten largest holdings make up 76% of its $1.69B portfolio in Q4 2024.
  • Kynam Capital Management opened 6 new positions and closed 1 in Q4 2024.
  • Kynam Capital Management's portfolio value rose 30% quarter-over-quarter to $1.69B.

Based on Kynam Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.